MAPT and Mental deterioration: Particularly, the recently completed Phase 2 clinical trial of AADvac1, an active immunotherapy targeting tau mid-region indicated that therapy may potentially slow cognitive decline in a subgroup of patients with ascertained tau pathology (Novak et al., 2021).